The following Structured Product Label (SPL) was submitted to the FDA by Rigel Pharmaceuticals, Inc. for the product Rezlidhia (NDC 71332-005). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding warning: differentiation syndrome, 1 indications and usage, 2.1 patient selection, 2.2 recommended dosage, 2.3 monitoring and dosage modifications for adverse reactions, 3 dosage forms and strengths, 4 contraindications, 5.1 differentiation syndrome, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Differentiation syndrome, which can be fatal, can occur with REZLIDHIA treatment. Symptoms may include dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, hypotension, fever, and weight gain.
If differentiation syndrome is suspected, withhold REZLIDHIA and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution [see Warnings and Precautions (5.1)].
Relapsed or Refractory Acute Myeloid Leukemia
REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration (2.1), Clinical Pharmacology (12.1), and Clinical Studies (14.1)].
Select patients for the treatment of relapsed or refractory AML with REZLIDHIA based on the presence of IDH1 mutations in blood or bone marrow [see Clinical Trials (14.1)]. Information on FDA- approved tests for the detection of IDH1 mutations in AML is available at http://www.fda.gov/CompanionDiagnostics.
The recommended dosage of REZLIDHIA is 150 mg taken orally twice daily until disease progression or unacceptable toxicity. Administer REZLIDHIA capsules orally about the same time each day. Do not administer 2 doses within 8 hours. Take on an empty stomach at least 1 hour before or 2 hours after a meal [see Clinical Pharmacology (12.3)]. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
Swallow REZLIDHIA capsules whole. Do not break, open, or chew the capsules. If a dose of REZLIDHIA is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of REZLIDHIA is missed or not taken at the usual time, administer the dose as soon as possible and at least 8 hours prior to the next scheduled dose. Return to the normal schedule the following day.
Assess blood counts, and blood chemistries including liver function tests prior to initiation of REZLIDHIA, at least once weekly for the first two months; once every other week for the third month; once in the fourth month, and once every other month for the duration of therapy. Manage any abnormalities promptly [see Warnings and Precautions (5.1 and 5.2) and Adverse Reactions (6.1)].
Interrupt dosing or reduce dose for toxicities. See Table 1 for dosage modification guidelines.
| Adverse Reactions | Recommended Action |
|
Differentiation Syndrome [see Warnings and Precautions (5.1)] |
|
|
Noninfectious leukocytosis [see Adverse Reactions (6.1)] |
|
|
Grade 3 Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening. Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03). hepatotoxicity[see Warnings and Precautions (5.2)] |
|
|
Grade 4 [see Warnings and Precautions (5.2)] |
|
|
Other Grade 3 [see Adverse Reactions (6.1)] |
|
Capsules: 150 mg opaque white capsules imprinted with "OLU 150".
None.
REZLIDHIA can cause differentiation syndrome. In the clinical trial of REZLIDHIA in patients with relapsed or refractory AML, differentiation syndrome occurred in 16% (25/153) of patients, with grade 3 or 4 differentiation syndrome occurring in 8% of patients treated, and fatalities in 1% of patients [see Adverse Reactions (6.1)]. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal. Symptoms of differentiation syndrome in patients treated with REZLIDHIA included leukocytosis, dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, fever, edema, pyrexia, and weight gain. Of the 25 patients who experienced differentiation syndrome, 19 (76%) recovered after treatment or after dosage interruption of REZLIDHIA. Differentiation syndrome occurred as early as 1 day and up to 18 months after REZLIDHIA initiation and has been observed with or without concomitant leukocytosis.
If differentiation syndrome is suspected, temporarily withhold REZLIDHIA and initiate systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours) for a minimum of 3 days and until resolution of signs and symptoms. If concomitant leukocytosis is observed, initiate treatment with hydroxyurea, as clinically indicated. Taper corticosteroids and hydroxyurea after resolution of symptoms. Differentiation syndrome may recur with premature discontinuation of corticosteroids and/or hydroxyurea treatment. Institute supportive measures and hemodynamic monitoring until improvement; withhold dose of REZLIDHIA and consider dose reduction based on recurrence [see Dosage and Administration (2.3)].
REZLIDHIA can cause hepatotoxicity, presenting as increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased blood alkaline phosphatase, and/or elevated bilirubin. Of 153 patients with relapsed or refractory AML who received REZLIDHIA, hepatotoxicity occurred in 23% of patients; 13% experienced grade 3 or 4 hepatotoxicity [see Adverse Reactions (6.1)]. One patient treated with REZLIDHIA in combination with azacitidine in the clinical trial, a combination for which REZLIDHIA is not indicated, died from complications of drug-induced liver injury. The median time to onset of hepatotoxicity in patients with relapsed or refractory AML treated with REZLIDHIA was 1.2 months (range: 1 day to 17.5 months) after REZLIDHIA initiation, and the median time to resolution was 12 days (range: 1 day to 17 months). The most common hepatotoxicities were elevations of ALT, AST, blood alkaline phosphatase, and blood bilirubin.
Monitor patients frequently for clinical symptoms of hepatic dysfunction such as fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Obtain baseline liver function tests prior to initiation of REZLIDHIA, at least once weekly for the first two months, once every other week for the third month, once in the fourth month, and once every other month for the duration of therapy. If hepatic dysfunction occurs, withhold, reduce, or permanently discontinue REZLIDHIA based on recurrence/severity [see Dosage and Administration (2.3)].
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Relapsed or Refractory AML
The safety of REZLIDHIA 150 mg administered twice daily was evaluated in 153 adults with relapsed or refractory AML with an IDH1 mutation [see Clinical Studies (14.1)]. Among the 153 patients who received REZLIDHIA, 35% were exposed for at least 6 months and 21% were exposed for at least 1 year. The median duration of exposure to REZLIDHIA was 4.7 months (range: 0.1 to 34 months).
Serious adverse reactions occurred in 25% of patients who received REZLIDHIA. Serious adverse reactions in ≥5% included differentiation syndrome (9%) and transaminitis (6%). Fatal adverse reactions occurred in 1% of patients who received REZLIDHIA, due to differentiation syndrome.
Permanent discontinuation of REZLIDHIA due to an adverse reaction occurred in 8% of patients. Adverse reactions leading to permanent discontinuation in ≥1% of patients included transaminitis, differentiation syndrome, and gallbladder disorders.
Dosage interruptions of REZLIDHIA due to an adverse reaction occurred in 32% of patients. Adverse reactions which required dosage interruption in >5% of patients included transaminitis and differentiation syndrome.
Dose reductions of REZLIDHIA due to an adverse reaction occurred in 11% of patients. Adverse reactions which required dose reductions in ≥2% of patients included transaminitis.
The most common (≥20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased, alanine aminotransferase increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea and transaminitis.
Table 2 summarizes the adverse reactions in the clinical trial for relapsed or refractory AML.
| Olutasidenib 150 mg BID N=153 | ||
| Body System Adverse Reaction | All Grades (%) | Grade 3 or 4 (%) |
| Gastrointestinal Disorders | ||
| Nausea | 38 | 0 |
| Constipation | 26 | 0 |
| Mucositis Mucositis includes gingival hypertrophy, gingivitis, gingivitis ulcerative, oral disorder, colitis, mouth ulceration, stomatitis, tongue ulceration, oral pain, oropharyngeal pain, pharyngitis, proctalgia, and colitis ischemic. | 23 | 3 |
| Diarrhea | 20 | 1 |
| Abdominal pain Includes multiple similar adverse reaction terms. | 18 | 1 |
| Vomiting | 17 | 1 |
| General Disorders and Administration Site Conditions | ||
| Fatigue/malaise | 36 | 3 |
| Pyrexia | 24 | 1 |
| Edema | 18 | 3 |
| Musculoskeletal and Connective Tissue Disorders | ||
| Arthralgia Arthralgia grouped term includes arthralgia, bone pain, back pain, neck pain, pain in extremity, arthritis, joint effusion, joint range of motion decreased, and joint swelling. | 28 | 3 |
| Blood System and Lymphatic Disorders | ||
| Leukocytosis | 25 | 9 |
| Differentiation syndrome Includes fatal adverse reaction. 'Symptoms of differentiation syndrome in patients treated with REZLIDHIA included leukocytosis, dyspnea, pulmonary infiltrates/pleuropericardial effusion, kidney injury, fever, edema, pyrexia, and weight gain. | 16 | 8 |
| Respiratory, Thoracic and Mediastinal Disorders | ||
| Dyspnea Dyspnea grouped term includes acute respiratory distress syndrome, dyspnea, dyspnea exertional, hypoxia, oxygen saturation decreased, respiratory distress, respiratory failure. | 24 | 5 |
| Cough | 17 | 1 |
| Skin and subcutaneous tissue disorders | ||
| Rash | 24 | 1 |
| Investigations | ||
| Transaminitis Transaminitis grouped term includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased, hypertransaminasemia, liver function test abnormal, liver function test increased, transaminases increased, hepatitis acute, and blood alkaline phosphatase increased. | 20 | 12 |
| Metabolism and Nutrition Disorders | ||
| Decreased appetite | 16 | 2 |
| Nervous System Disorders | ||
| Headache | 13 | 0 |
| Vascular Disorders | ||
| Hypertension | 10 | 5 |
Clinically relevant adverse reactions in <10% of patients who received REZLIDHIA include:
Table 3 summarizes the laboratory abnormalities in the clinical trial for relapsed or refractory AML.
| Olutasidenib The denominator used to calculate the rate varied from 143 to 152 based on the number of patients with a baseline value and at least one post-treatment value. | ||
| Parameter | All Grades (%) | Grade 3 or 4 (%) |
| Aspartate aminotransferase increased | 47 | 10 |
| Alanine aminotransferase increased | 46 | 13 |
| Potassium decreased | 46 | 9 |
| Sodium decreased | 42 | 7 |
| Alkaline phosphatase increased | 42 | 7 |
| Creatinine increased | 38 | 2 |
| Lymphocytes increased | 26 | 3 |
| Bilirubin increased | 26 | 2 |
| Uric acid increased | 25 | 3 |
| Lipase increased | 24 | 8 |
Strong or Moderate CYP3A4 Inducers
Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers.
Olutasidenib is a CYP3A substrate. Concomitant use of REZLIDHIA with a strong CYP3A inducer decreases olutasidenib Cmax and AUC, which may reduce REZLIDHIA efficacy [see Clinical Pharmacology (12.3)].
Concomitant use of REZLIDHIA with a moderate CYP3A inducer may also decrease olutasidenib Cmax and AUC, which may also reduce REZLIDHIA efficacy, based on observations from concomitant use with a strong CYP3A inducer.
Sensitive CYP3A Substrates
Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates prescribing information. If concomitant use is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
Olutasidenib induces CYP3A. Concomitant use of REZLIDHIA may decrease plasma concentrations of sensitive CYP3A substrates, which may reduce the substrate’s efficacy [see Clinical Pharmacology (12.3)].
Risk Summary
Based on animal embryo-fetal toxicity studies, REZLIDHIA may cause fetal harm when administered to a pregnant woman. There are no available data on REZLIDHIA use in pregnant women to evaluate for a drug-associated risk.
In embryo-fetal development studies, oral olutasidenib resulted in embryo-fetal death and altered fetal growth when administered to pregnant rats and rabbits during the period of organogenesis at exposures up to 10 times and 0.7 times, respectively, the human exposure at the recommended daily dose (see Data). Advise pregnant women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.
Data
Animal Data
Olutasidenib was administered twice daily via oral gavage at dose levels of 25, 125, or 250 mg/kg/dose (50, 250, or 500 mg/kg/day) to pregnant rats during organogenesis (gestation days 6-17). An increase in fetal supernumerary rib was observed at the high dose (10 times the AUC at the clinical dose of 150 mg BID). In a pilot study, administration of olutasidenib orally to pregnant rats during organogenesis resulted in an increase in post-implantation loss at doses of 250 and 450 mg/kg/day (9 and 10 times the AUC at the clinical dose of 150 mg BID).
Olutasidenib was administered twice daily via oral gavage at dose levels of 10, 20, or 40 mg/kg/dose (20, 40, or 80 mg/kg/day) to pregnant rabbits during the period of organogenesis (gestation days 7- 20). Maternal toxicity noted as reduced body weight gain occurred at 80 mg/kg/day. An increase in fetal supernumerary rib and increased post-implantation loss occurred at the high dose of 80 mg/kg/day (0.7 times the AUC at the clinical dose of 150 mg BID).
Risk Summary
There are no data on the presence of olutasidenib or its metabolites in human milk, the effects on the breastfed child, or milk production. Because many drugs are excreted in human milk, and due to the potential for adverse reactions in a breastfed child, advise women not to breastfeed during treatment with REZLIDHIA and for 2 weeks after the last dose.
The safety and effectiveness of REZLIDHIA have not been established in pediatric patients.
Among the 153 patients with relapsed or refractory AML with an IDH1 mutation treated with REZLIDHIA, 116 (76%) were 65 years of age or older and 48 (31%) were 75 years or older. No overall differences in effectiveness were observed between patients 65 years and older and younger patients. Compared to patients younger than 65 years of age, an increase in incidence of hepatotoxicity and hypertension was observed in patients ≥65 years of age.
No dosage modification is recommended for patients with mild to moderate renal impairment (creatinine clearance [CLcr] 30 to <90 mL/min, as estimated by Cockcroft-Gault). The recommended dosage of REZLIDHIA has not been established in patients with severe renal impairment (CLcr 15 to 29 mL/min as estimated by Cockcroft-Gault), kidney failure (CLcr <15 mL/min, as estimated by Cockcroft-Gault), and patients on dialysis [see Clinical Pharmacology (12.3)].
No dosage modification is recommended for patients with mild (total bilirubin ≤ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST) or moderate (total bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment [see Clinical Pharmacology (12.3)]. In patients with mild or moderate hepatic impairment, closely monitor for increased probability of differentiation syndrome [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. The recommended dosage of REZLIDHIA has not been established in patients with severe hepatic impairment (total bilirubin >3 times ULN with any AST) [see Clinical Pharmacology (12.3)].
Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. The chemical name is (S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile. The chemical structure is:
Chemical Structure (Struct 01)
The molecular formula is C18H15ClN4O2 and the molecular weight is 354.79 g/mol. Olutasidenib is a white to off-white to brown powder that is practically insoluble in aqueous solutions between pH 1.2 and 7.4.
REZLIDHIA (olutasidenib) is available as hard gelatin capsules for oral administration. Each capsule contains 150 mg olutasidenib and the following ingredients: croscarmellose sodium, magnesium stearate and microcrystalline cellulose. The capsule shell contains gelatin and titanium dioxide. Each capsule is printed with black ink containing ferrosoferric oxide, propylene glycol, and shellac.
Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of olutasidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of olutasidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations in patients with AML are R132H and R132C substitutions.
In vitro, olutasidenib inhibited mutated IDH1 R132H, R132L, R132S, R132G, and R132C proteins; wild-type IDH1 or mutated IDH2 proteins were not inhibited. Olutasidenib inhibition of mutant IDH1 led to decreased 2-HG levels in vitro and in in vivo xenograft models.
The mean [% coefficient of variation (%CV)] reduction in 2-HG plasma concentration was 59.1% (122%) by pre-dose Cycle 2 and was sustained throughout the treatment period in patients with AML and IDH1 mutations following the approved recommended olutasidenib dosage.
Increased olutasidenib exposure was correlated with the increased probability of differentiation syndrome and Grade ≥3 hepatotoxicity in patients with AML following the approved recommended olutasidenib dosage.
Cardiac Electrophysiology
The largest mean increase in QTc interval was 6.2 msec (upper 90% confidence interval = 9.7 msec) in 33 patients with advanced hematologic malignancies with an IDH1 mutation following a single dose and multiple doses of the approved recommended olutasidenib dosage under fasted conditions. This increase in the QTc interval was concentration dependent.
Increased QT prolongation is expected with increased exposures of olutasidenib under a fed condition compared to that under fasting conditions [see Clinical Pharmacology (12.3)]. The clinical impact of this increase could not be determined because QTc intervals were not evaluated at higher olutasidenib exposures.
The pharmacokinetics of olutasidenib have been characterized in patients with AML following the approved recommended dosage, unless otherwise specified.
The mean (%CV) olutasidenib steady-state daily area under the plasma drug concentration over time curve (AUC0-12-h,ss) is 43050 (34.0%) ng·h/mL and steady-state maximum plasma concentration (Cmax,ss) is 3573 (45.6%) ng/mL following the approved recommended dosage.
Olutasidenib Cmax and AUC increase less-than proportionally over a dosage range from 100 mg to 300 mg (0.33 to 1 time the recommended total daily dose); however, this finding should not affect the recommended dosage of REZLIDHIA. Olutasidenib accumulation ratios ranging from 7.7 and 9.5 were observed following the approved recommended dosage. Steady-state plasma levels are reached within 14 days.
Absorption
The median (min, max) time to maximum concentration (tmax) of olutasidenib is approximately 4 (1, 8) hours following a single oral dose of 150 mg.
Effect of Food
The mean (CV%) of olutasidenib Cmax increased by 191% (20.6%) and AUCinf increased by 83% (18.3%) following administration of a single 150 mg dose of olutasidenib with a high-fat meal (approximately 800 to 1,000 calories, with approximately 50% of total caloric content of the meal from fat) in healthy subjects.
Distribution
The mean (CV%) apparent volume of distribution of olutasidenib is 319 (28.1%) L. The plasma protein binding of olutasidenib is approximately 93%.
Elimination
The mean (CV%) half-life (t1⁄2) of olutasidenib is approximately 67 (51.2%) hours and the mean (CV%) apparent oral clearance (CL/F) of olutasidenib is 4 (60.5%) L/h.
Metabolism
Olutasidenib metabolism involves N-dealkylation, demethylation, oxidative deamination followed by oxidation, mono-oxidation with subsequent glucuronidation. Olutasidenib is primarily (90%) metabolized by cytochrome P450(CYP)3A4, with minor contributions from CYP2C8, CYP2C9, CYP1A2, and CYP2C19.
Excretion
Following a single oral radiolabeled olutasidenib dose of 150 mg to healthy subjects, approximately 75% of olutasidenib was recovered in feces (35% unchanged) and 17% in the urine (1% unchanged).
Specific Populations
No clinically significant differences in the pharmacokinetics of olutasidenib were observed based on age (28 to 90 years), sex, body weight (36 to 145 kg), mild to moderate renal impairment (creatinine clearance [CLcr] 30 to <90mL/min as estimated by Cockcroft-Gault), or mild (total bilirubin ≤ULN and any AST >ULN or total bilirubin >1 to 1.5 times ULN and any AST) or moderate (total bilirubin >1.5 to 3 times ULN and any AST) hepatic impairment.
The effect of severe renal impairment (CLcr 15 to 29 mL/min, as estimated by Cockcroft-Gault), kidney failure (CLcr <15 mL/min, as estimated by Cockcroft-Gault), patients on dialysis, and patients with severe hepatic impairment (total bilirubin >3 x ULN with any AST) on olutasidenib pharmacokinetics is unknown or not fully characterized.
Drug Interaction Studies
Clinical Studies
Strong CYP3A and P-glycoprotein (P-gp) Inhibitors: No clinically significant differences in olutasidenib pharmacokinetics were observed when used concomitantly with multiple doses of a strong CYP3A and P-gp inhibitor (itraconazole).
Strong CYP3A4 Inducers: Olutasidenib Cmax decreased by 43% and AUC by 80% when used concomitantly with multiple doses of a strong CYP3A inducer (rifampin).
In vitro Studies
CYP Enzymes: Olutasidenib induces CYP3A4, CYP2B6, CYP1A2, CYP2C8 and CYP2C9.
Olutasidenib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5.
Transporter Systems: Olutasidenib is not a substrate of BCRP, BSEP, MRP2, MRP3, or MRP4.
Ivosidenib does not inhibit BCRP, OATP1B1, OATP1B3, OAT1, and OCT2 at clinically relevant concentrations. Ivosidenib is an inhibitor of OAT3 and P-gp.
Olutasidenib is an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT3, OCT2, MATE1, and MATE2K. Olutasidenib does not inhibit BSEP, MRP2, MRP3, MRP4, or OAT1.
Carcinogenicity studies have not been conducted with olutasidenib. Olutasidenib was not genotoxic in the in vitro bacterial reverse mutation (Ames), in vitro human lymphocyte micronucleus, and in vivo rat bone marrow micronucleus assays. Fertility studies in animals have not been conducted with olutasidenib.
Olutasidenib was phototoxic in vitro and in vivo. In pigmented rats, oral administration of olutasidenib for 3 consecutive days followed by exposure to UV light 2 hours after the last dose resulted in skin erythema which persisted for 72 hours.
The efficacy of REZLIDHIA was evaluated in an open-label, single-arm, multicenter clinical trial (Study 2102-HEM-101, NCT02719574) in 147 adult patients with relapsed or refractory AML with an IDH1 mutation.
IDH1 mutations in blood or bone marrow were confirmed retrospectively using the Abbott RealTime™ IDH1 Assay. REZLIDHIA was given orally at a dose of 150 mg twice daily until disease progression, development of unacceptable toxicity, or hematopoietic stem cell transplantation. Sixteen of the 147 patients (11%) underwent stem cell transplantation following REZLIDHIA treatment.
The baseline demographic and disease characteristics are shown in Table 4.
| Demographic and Disease Characteristics | REZLIDHIA (150 mg twice daily) N=147 |
| Demographics | |
| Age (Years) Median (Min, Max) | 71 (32, 87) |
| Age Categories, n (%) | |
| <65 years | 37 (25) |
| ≥65 years to <75 years | 65 (44) |
| ≥75 years | 45 (31) |
| Sex, n (%) | |
| Male | 74 (50) |
| Female | 73 (50) |
| Race, n (%) | |
| White | 67 (46) |
| Black or African American | 5 (3) |
| Asian | 5 (3) |
| Native Hawaiian/Other Pacific Islander | 0 (0) |
| Other/Not provided | 70 (48) |
| Disease Characteristics | |
| ECOG PS, n (%) | |
| 0 | 45 (31) |
| 1 | 76 (52) |
| 2 | 23 (16) |
| IDH1 Mutation, n (%) Using central IDH1 assay testing results. | |
| R132C | 85 (58) |
| R132H | 35 (24) |
| R132G | 12 (8) |
| R132S | 11 (7) |
| R132L | 4 (3) |
| Type of AML, n (%) | |
| De novo AML | 97 (66) |
| Secondary AML | 50 (34) |
| Cytogenetic Risk Status Cytogenetic risk categorization was investigator reported by NCCN or ELN guidelines. , n (%) | |
| Favorable | 6 (4) |
| Intermediate | 107 (73) |
| Poor | 25 (17) |
| Unknown | 9 (6) |
| Relapsed/Refractory Patient Category | |
| Primary Refractory | 46 (31) |
| Untreated Relapse May be first or subsequent relapse. | 81 (55) |
| Refractory Relapse | 20 (14) |
| Relapse Number | |
| 0 | 46 (31) |
| 1 | 87 (59) |
| 2 | 11 (8) |
| ≥3 | 3 (2) |
| Prior Stem Cell Transplantation for AML, n (%) | 17 (12) |
| Transfusion Dependent at Baseline Transfusion-Dependent at Baseline is defined as receiving a transfusion within 8 weeks prior to first dose of olutasidenib or noting transfusion dependence prior to coming on study. , n (%) | 86 (59) |
| Median Number of Prior Therapies (Min, Max) | 2 (1,7) |
Efficacy was established on the basis of the rate of complete remission (CR) plus complete remission with partial hematologic recovery (CRh), the duration of CR+CRh, and the rate of conversion from transfusion dependence to transfusion independence. The efficacy results are shown in Table 5. The median follow-up was 10.2 months (range: 0.2 to 38.1 months) and median treatment duration was 4.7 months (range: 0.1 to 26.0 months).
| Endpoint | REZLIDHIA (150 mg twice daily) N=147 |
| CR+CRh CR (complete remission) was defined as <5% blasts in the bone marrow, no blasts with Auer rods, no extramedullary disease, and full recovery of peripheral blood counts (platelets >100,000/microliter and absolute neutrophil counts [ANC] >1,000/microliter); CRh (complete remission with partial hematologic recovery) was defined as <5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets >50,000/microliter and ANC >500/microliter). ,CR+CRh rate was consistent across all baseline demographic and baseline disease characteristic subgroups with the exception of IDH1 R132H mutation (CR+CRh 17%). n (%) | 51 (35) |
| 95% CI | (27, 43) |
| Median DOCR+CRh Duration of response is defined as the time from the date of the first response to the date of the relapse or death. Patients who did not relapse were censored at the date of last response assessment. + indicates censored observation. (months) | 25.9 |
| 95% CI | (13.5, NR) |
| CR | 47 (32) |
| 95% CI | (25, 40) |
| Median DOCR | 28.1 |
| 95% CI | (13.8, NR) |
| CRh | 4 (2.7) |
| 95% CI | (0.7, 6.8) |
| Observed DOCRh | 1.8, 5.6, 13.5, 28.5+ |
| CI: confidence interval; NR = not reached | |
Of the patients who achieved a CR or CRh, the median time to CR or CRh was 1.9 months (range: 0.9 to 5.6 months). All patients that achieved a best response of CR or CRh did so within 5.6 months of initiating REZLIDHIA.
Overall, among the 86 patients who were dependent on red blood cell (RBC) and/or platelet transfusions at baseline, 29 (34%) became independent of RBC and platelet transfusions during any 56-day post-baseline period. Of the 61 patients who were independent of both RBC and platelet transfusions at baseline, 39 (64%) remained transfusion independent during any 56-day post- baseline period.
How Supplied
| Capsule Strength | Description | Package Configuration | NDC Number |
| 150 mg | White hard gelatin capsules with black ink print "OLU 150" | White high-density polyethylene (HDPE) bottle with child-resistant closure | 71332-005-01 |
| Each bottle contains 30 capsules |
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)
[see USP Controlled Room Temperature].
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Differentiation Syndrome
Advise patients of the risks of developing differentiation syndrome as early as 1 day after start of therapy and up to 18 months on treatment. Ask patients to immediately report any symptoms suggestive of differentiation syndrome, such as fever, cough or difficulty breathing, decreased urinary output, low blood pressure, weight gain, or swelling of their arms or legs, to their healthcare provider for further evaluation [see Warnings and Precautions (5.1)].
Hepatotoxicity
Advise patients of the potential for hepatic effects and to immediately report any associated signs and symptoms such as right upper abdominal discomfort, dark urine, jaundice, anorexia, or fatigue to their healthcare provider for further evaluation [see Warnings and Precautions (5.2)].
Gastrointestinal Adverse Reactions
Advise patients on the risks of experiencing gastrointestinal reactions such as nausea, constipation, diarrhea, vomiting, abdominal pain, and mucositis. Ask patients to report these events to their healthcare provider and advise patients how to manage them [see Adverse Reactions (6.1)].
Lactation
Advise women not to breastfeed during treatment with REZLIDHIA and for 2 weeks after the last dose [see Use in Specific Populations (8.2)].
Dosing and Storage Instructions
Manufactured by Catalent Greenville, Inc. 1240 Sugg Pkwy, Greenville, NC 27834
Manufactured for Rigel Pharmaceuticals, Inc. South San Francisco, CA 94080
REZLIDHIA™ is a trademark of Rigel Pharmaceuticals, Inc.
For more information go to www.REZLIDHIA.com or call 1-800-983-1329.
12/2022 Rev 02
MEDICATION GUIDE REZLIDHIA™ (REZ-LID-EE-AH) | |
What is the most important information I should know about REZLIDHIA? REZLIDHIA may cause serious side effects including:
If you develop signs and symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine or a medicine called hydroxyurea and may monitor you in the hospital. See "What are the possible side effects of REZLIDHIA?" for more information about side effects. | |
What is REZLIDHIA? REZLIDHIA is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation when the disease has come back or has not improved after previous treatment(s). Your healthcare provider will perform a test to make sure that REZLIDHIA is right for you. It is not known if REZLIDHIA is safe and effective in children. | |
Before taking REZLIDHIA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. | |
How should I take REZLIDHIA?
| |
What are the possible side effects of REZLIDHIA? REZLIDHIA may cause serious side effects, including:
The most common side effects of REZLIDHIA in adults with AML include: Tell your healthcare provider if you have any nausea, constipation, diarrhea, vomiting, stomach pain or mouth sores. Your healthcare provider will do blood tests before you start and during treatment with REZLIDHIA. Your healthcare provider may decrease, temporarily hold, or permanently stop your treatment with REZLIDHIA if you develop certain side effects. These are not all the possible side effects of REZLIDHIA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |
How should I store REZLIDHIA? Store REZLIDHIA at room temperature from 68°F to 77°F (20°C to 25°C). Keep REZLIDHIA and all medicines out of the reach of children. | |
General information about the safe and effective use of REZLIDHIA Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take REZLIDHIA for conditions for which it was not prescribed. Do not give REZLIDHIA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about REZLIDHIA that is written for healthcare professionals. | |
What are the ingredients in REZLIDHIA? Active ingredient: olutasidenib Inactive ingredients: Manufactured by Catalent Greenville, Inc. 1240 Sugg Pkwy, Greenville, NC 27834 | |
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Issued: 12/2022 |
NDC: 71332-005-01
Rx only
REZLIDHIA
olutasidenib capsules
150 mg
Dispense the enclosed Medication Guide to each patient.
30 capsules
150 mg Tablet 30-count Carton Label (Principal Display Panel)
* Please review the disclaimer below.
